Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.44USD
19 Mar 2019
Change (% chg)

$1.27 (+0.93%)
Prev Close
$137.17
Open
$137.61
Day's High
$138.81
Day's Low
$137.49
Volume
2,056,426
Avg. Vol
2,740,551
52-wk High
$148.97
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Oxfam America Says Urges J&J Shareholders To Vote For Resolution At Annual Meeting Of J&J
Tuesday, 19 Mar 2019 12:35pm EDT 

March 19 (Reuters) - Johnson & Johnson ::OXFAM AMERICA SAYS URGES J&J SHAREHOLDERS TO VOTE FOR RESOLUTION AT THE ANNUAL MEETING OF JOHNSON AND JOHNSON - SEC FILING.OXFAM AMERICA - RESOLUTION ASKS J&J TO REPORT EXTENT TO WHICH RISKS RELATED TO PUBLIC CONCERN OVER DRUG PRICING ARE INTEGRATED INTO SENIOR EXECUTIVES' COMPENSATION ARRANGEMENTS.  Full Article

New Phase 3 Stelara (Ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
Monday, 11 Mar 2019 08:00am EDT 

March 11 (Reuters) - Johnson & Johnson ::NEW PHASE 3 STELARA (USTEKINUMAB) DATA SHOW POSITIVE RESULTS AS MAINTENANCE THERAPY IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS.JANSSEN - SIGNIFICANTLY GREATER PROPORTION OF ADULT PATIENTS WITH MODERATE TO SEVERE UC GETTING STELARA SC MAINTENANCE THERAPY WERE IN CLINICAL REMISSION AT 1 YEAR.  Full Article

Imbruvica (Ibrutinib) Combination Regimen To Treat Waldenström's Macroglobulinemia Approved Through Health Canada Priority Review
Friday, 8 Mar 2019 08:00am EST 

March 8 (Reuters) - Johnson & Johnson ::IMBRUVICA (IBRUTINIB) COMBINATION REGIMEN TO TREAT WALDENSTRÖM'S MACROGLOBULINEMIA APPROVED THROUGH HEALTH CANADA PRIORITY REVIEW.JANSSEN SAYS APPROVAL EXPANDS INDICATION OF IMBRUVICA IN WM.  Full Article

Janssen Announces U.S. FDA Approval Of Spravato CII Nasal Spray For Adults With Treatment-Resistant Depression
Tuesday, 5 Mar 2019 08:17pm EST 

March 5 (Reuters) - Janssen: :JANSSEN ANNOUNCES U.S. FDA APPROVAL OF SPRAVATO™ (ESKETAMINE) CIII NASAL SPRAY FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION (TRD) WHO HAVE CYCLED THROUGH MULTIPLE TREATMENTS WITHOUT RELIEF.JANSSEN - ANNOUNCED U.S. FDA HAS APPROVED SPRAVATO (ESKETAMINE) CIII NASAL SPRAY FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION.  Full Article

Johnson & Johnson Reports 8.7 Percent Passive Stake In Meiragtx Holdings- SEC Filing
Monday, 4 Mar 2019 05:47pm EST 

March 4 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON REPORTS 8.7 PERCENT PASSIVE STAKE IN MEIRAGTX HOLDINGS PLC AS OF MARCH 1, 2019 - SEC FILING.  Full Article

Adorx Announces Collaboration With Johnson & Johnson Innovation
Thursday, 28 Feb 2019 03:00am EST 

Feb 28 (Reuters) - Adorx Therapeutics::ADORX THERAPEUTICS ANNOUNCES COLLABORATION WITH JOHNSON & JOHNSON INNOVATION TO DEVELOP NOVEL LUNG CANCER THERAPEUTICS.ADORX THERAPEUTICS - FINANCIAL TERMS OF COLLABORATION WITH JOHNSON & JOHNSON WERE NOT DISCLOSED.ADORX THERAPEUTICS - UNDER AGREEMENT, CO GRANTED EXCLUSIVE OPTION TO RESEARCH, DEVELOP, COMMERCIALISE NOVEL ANTAGONISTS WITHIN ADORX PORTFOLIO.ADORX THERAPEUTICS - UNDER TERMS OF AGREEMENT GROUPS WILL COLLABORATE ON DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT ACTIVITIES.  Full Article

Competition Bureau Completes Investigation Into Alleged Abuse Of Dominance By Janssen Inc
Wednesday, 20 Feb 2019 04:15pm EST 

Feb 20 (Reuters) - Johnson & Johnson ::COMPETITION BUREAU COMPLETES INVESTIGATION INTO ALLEGED ABUSE OF DOMINANCE BY JANSSEN INC..COMPETITION BUREAU - CONCLUDED THERE IS INSUFFICIENT EVIDENCE TO SHOW JANSSEN'S CONDUCT SUBSTANTIALLY LESSENED/PREVENTED COMPETITION IN RELEVANT MARKET.  Full Article

Biomx Raises $32 Million In Series B Financing
Wednesday, 20 Feb 2019 07:30am EST 

Feb 20 (Reuters) - BiomX Ltd::BIOMX RAISES $32 MILLION IN SERIES B FINANCING.BIOMX - FINANCING WAS LED BY EXISTING INVESTORS ORBIMED, JOHNSON & JOHNSON INNOVATION - JJDC, INC., TAKEDA VENTURES & OTHERS.BIOMX-FINANCING PROCEEDS TO BE USED PRIMARILY TO ADVANCE CO'S LEADING DRUG CANDIDATES FOR TREATMENT OF ACNE & INFLAMMATORY BOWEL DISEASE TO CLINIC.  Full Article

Johnson & Johnson - Prelim Results From Phase 2 Study In Adults With Metastatic Castration-Resistant Prostate Cancer And DNA-Repair Pathway Defects
Thursday, 14 Feb 2019 08:00am EST 

Feb 14 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES PRELIMINARY RESULTS FROM PHASE 2 GALAHAD STUDY IN ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND DNA-REPAIR PATHWAY DEFECTS (DRD).JANSSEN - DATA SHOWED NIRAPARIB DEMONSTRATED ORR OF ABOUT 40 PERCENT IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, DNA-REPAIR PATHWAY DEFECTS.  Full Article

U.S. FDA Approves Darzalex Split-Dosing Regimen
Tuesday, 12 Feb 2019 08:00am EST 

Feb 12 (Reuters) - Johnson & Johnson ::U.S. FDA APPROVES DARZALEX® (DARATUMUMAB) SPLIT-DOSING REGIMEN.JANSSEN PHARMACEUTICAL - U.S. FDA APPROVES DARZALEX® (DARATUMUMAB) SPLIT-DOSING REGIMEN.  Full Article

Photo

J&J and Sientra get FDA warning letters over breast implants

The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.